To view product information for the FilterWire EZ Embolic Protection System specific to use in carotid arteries,
click here.
With its advanced technology designed for simplicity and effectiveness, the FilterWire EZ Embolic Protection System is intended to deliver efficient, predictable protection.
Product Information
Easy to Use
- Reliable Wall Apposition – Self-conforming filter loop is designed to provide 360º apposition in both straight and curved anatomy.
- Easy Delivery – Efficient design reduces preparation time and simplifies device deployment.
- Efficient Debris Capture – Uniform, 110-micron-pore filter is designed to permit continuous blood flow while maintaining embolic capture efficiency.
Built-in Versatility
- Dual-Indication Use – Approved for both saphenous vein graft (SVG) and carotid indications.
- Simplified Filter Sizing – One product line provides coverage in vessels ranging between 2.25mm and 5.5mm for SVG procedures and between 3.5mm and 5.5mm for carotid procedures.
Clinically Effective
- The BLAZE and BLAZE II registries achieved a low 6.7% and 3.8% MACE rate, respectively, and confirmed the safety and performance of the FilterWire System in SVGs.*
Device Illustration
Device Highlights
• The FilterWire EZ System Minimum Landing Zone (distal edge of lesion to loop apex):
- 2.25mm - 3.5mm: ≥ 2.5cm
- 3.5mm - 5.5mm: ≥ 3.0cm
- Radiopaque Spring Tip (2.0cm and 3.0cm, respectively)
- 110 Micron Pore Filter
- Radiopaque Nitinol Loop
- Spinner Tube
- Proximal Stop
- PTFE Coated Wire (.014")
Additional Information
- 6F Guide Catheter Compatible
- Catalog Numbers and Descriptions:
- H749 20100-190 0 FilterWire EZ System 190cm
- H749 20100-300 0 FilterWire EZ System 300cm
- H749 50100-150 0 EZ Bent Tip Retrieval Sheath
New 2.25mm - 3.5mm device now available
- H749 39071-190 0 FilterWire EZ System 2.25mm - 3.5mm, 190cm
- H749 39071-300 0 FilterWire EZ System 2.25mm - 3.5mm, 300cm
*The BLAZE/BLAZE II registries showed low major adverse cardiac event (MACE) rates for the FilterWire EZ System. See BLAZE/BLAZE II trial designs for more information and definitions of MACE rates. BLAZE II adjusted 30-day MACE based on predicted values for missing CK-MBs is 4.6%.
